登录  
 加关注
查看详情
   显示下一条  |  关闭
温馨提示!由于新浪微博认证机制调整,您的新浪微博帐号绑定已过期,请重新绑定!立即重新绑定新浪微博》  |  关闭

青山妩媚

新的一年,新的心情,新的挑战,新的起点...

 
 
 

日志

 
 

Important News in Bio-Pharma-2  

2009-02-19 17:20:17|  分类: Bio-Pharma |  标签: |举报 |字号 订阅

  下载LOFTER 我的照片书  |

       GPC, Agennix get $20M to fuel merger

Germany's GPC Biotech AG and Houston-based Agennix are planning to merge their oncology pipelines. In the deal, GPC is being merged into a new company which will have all of Agennix's shares along with 15 million euros--$20 million--injected by an investment company belonging to Dietmar Hopp, who has extensive biotech holdings.

The merger of their two pipelines will add Agennix's late-stage cancer drug talactoferrin. And shareholders will get a chance to vote on the merger in the first half of this year. The key investor in this deal is Hopp, a wealthy German with a keen interest in drug development. His investment group, dievini Hopp Biotech, is providing the $20 million to complete the deal.

"Dievini focuses its investments on creating and building entrepreneurial and sustainable biotech organizations to foster the development of innovative new treatments for patients," says GPC CEO Bernd Seizinger. "This philosophy fits well with out goals for the new company."

The company will have three sites in Munich, Princeton, NJ and Houston.

NeuroSearch, Lilly ink multimillion-dollar CNS deal

NeuroSearch is getting a capital injection of $22 million after signing a new R&D pact with Eli Lilly. Lilly is providing $5 million of that as an upfront fee and $17 million in an equity investment in exchange for NeuroSearch's help to advance new medicines based on novel approaches to specific ion channel modulation. The partnership will focus on CNS programs.

Under the pact NeuroSearch will also gain $8 million to support its research work. And each new product that is approved can qualify for up to $320 million in milestones and additional royalties.

The deal is an "excellent example of our corporate strategy as a fully integrated pharmaceutical network, where we are collaborating with researchers beyond our walls," says William Chin, Lilly vice president for discovery research and clinical investigation.

Akron Biotechnology Merging with AppliChem, a Leading BioChemicals Manufacturer

Akron Biotechnology Merging with AppliChem, a Leading BioChemicals Manufacturer
 
BOCA RATON, Fla. -- Mar 3, 2009 - Akron Biotechnology, LLC is pleased to announce its highly anticipated merger with the leading manufacturer of chemicals and biochemicals, AppliChem, GmbH.

AppliChem, located in Darmstadt Germany, and Akron Biotech, located in Boca Raton FL, USA are merging forces for the manufacturing and distribution of both companies' products. Commencing on March 2nd, 2009, Akron Biotech will take over AppliChem's operations in the Americas and will be called AppliChem, LLC.

AppliChem, LLC is committed to offering its customers the same high quality products including Animal Serum, Recombinant Proteins, Serum-Free Media and other cell-culture components in addition to AppliChem's full list of 4,000 products such as Amino Acids and Powder Media.

"The merger with AppliChem, GmbH will allow us to expand our product offering dramatically, and will accelerate our company's growth", said Akron Biotech's CEO, Dr. Claudia Zylberberg, "It presents an opportunity for us to expand our presence in the market by adding their full line." Dr. Zylberberg will continue to operate as the President and CEO of AppliChem, LLC.

"The chemistry between the two companies made this strategic alliance a natural fit", adds Dr. Markus Frasch, Managing Director of AppliChem, GmbH, "Their established market base in the US, Canada and South America, combined with their reputation for providing high quality products and excellent customer service will provide AppliChem the opportunity to expand its market base in these regions. "

AppliChem, GmbH and Akron Biotech will first join forces during Pittcon 2009 in Chicago, IL Booth#1122.

AppliChem, GmbH: Founded in 1992, AppliChem was established on the grounds of supplying high quality chemicals for chemical, biological, pharmaceutical and clinical research. AppliChem is ISO 9001 certified, hence, guaranteeing carefully controlled production and documentation. AppliChem offers Chemica, BioChemica, Custom Synthesis, Cell Culture Powder and more.

Ottoweg 4, DE-64291 Darmstadt, Germany, Ph: +49 (0)6151 9357-0/ Fax: +49 (0)6151 9357-11/ E-mail: service@applichem.com.

Applichem, LLC: Formerly known Akron Biotech, is an innovative biotechnology company focused on providing best-in-class cell culture components for Research and Product Development in Cell-Biology, Immunology, Pharmaceutical and Diagnostics. Products include: Animal Products, Human Products, Reagents and Media. Additionally, the company will carry AppliChem GmbH's full list.

3998 FAU Blvd., Suite 210, Boca Raton, FL 33431 Ph: 561.750.6120/ Fax: 561.750.6140 /E-mail: sales@applichem.com website: www.applichem.us.

 

  评论这张
 
阅读(367)| 评论(0)

历史上的今天

评论

<#--最新日志,群博日志--> <#--推荐日志--> <#--引用记录--> <#--博主推荐--> <#--随机阅读--> <#--首页推荐--> <#--历史上的今天--> <#--被推荐日志--> <#--上一篇,下一篇--> <#-- 热度 --> <#-- 网易新闻广告 --> <#--右边模块结构--> <#--评论模块结构--> <#--引用模块结构--> <#--博主发起的投票-->
 
 
 
 
 
 
 
 
 
 
 
 
 
 

页脚

网易公司版权所有 ©1997-2018